Our History and Approach
At ViiV Healthcare, addressing the challenges posed by HIV is our sole focus. We are the only pharmaceutical company wholly committed to HIV. With that dedication we bring a unique and innovative approach to researching effective HIV medicines, to improving access and care and to supporting individuals affected by HIV.
ViiV Healthcare was formed in November 2009 from two pharmaceutical companies, GlaxoSmithKline (GSK) and Pfizer. As separate companies they had already contributed to significant advances in the HIV/AIDS field, including production of the first licensed drug for AIDS and the first combination antiretroviral tablet. Shionogi joined ViiV Healthcare in 2012.
Here at ViiV Healthcare, we have a nimble approach that enables us to quickly adapt to the evolving challenges that the HIV epidemic brings. We currently have a broad portfolio of ten established products. Looking to the future, we have a pipeline of six innovative compounds in development and an active, ongoing effort to partner with other companies and institutions also focused on delivering innovation in HIV.
We are constantly searching for and building new partnerships, connections and collaborations to meet the evolving needs of physicians, people living with HIV and the broader HIV community. Our network of collaborations is growing and we are now supporting grassroots projects throughout the world. This has been enabled through our dynamic Positive Action, Positive Action for Children Fund and Positive Action Community Grants programmes.